- Home
- QSI vs NMRA Comparison
QSI vs NMRA Comparison
Compare QSI & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- NMRA
- Stock Information
- Founded
- QSI 2013
- NMRA 2019
- Country
- QSI United States
- NMRA United States
- Employees
- QSI N/A
- NMRA N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- NMRA
- Sector
- QSI Health Care
- NMRA
- Exchange
- QSI Nasdaq
- NMRA Nasdaq
- Market Cap
- QSI 226.8M
- NMRA 268.5M
- IPO Year
- QSI N/A
- NMRA 2023
- Fundamental
- Price
- QSI $1.73
- NMRA $1.96
- Analyst Decision
- QSI Strong Buy
- NMRA Hold
- Analyst Count
- QSI 3
- NMRA 8
- Target Price
- QSI $2.38
- NMRA $5.83
- AVG Volume (30 Days)
- QSI 13.4M
- NMRA 510.5K
- Earning Date
- QSI 11-11-2025
- NMRA 11-11-2025
- Dividend Yield
- QSI N/A
- NMRA N/A
- EPS Growth
- QSI N/A
- NMRA N/A
- EPS
- QSI N/A
- NMRA N/A
- Revenue
- QSI $3,412,000.00
- NMRA N/A
- Revenue This Year
- QSI N/A
- NMRA N/A
- Revenue Next Year
- QSI $219.33
- NMRA N/A
- P/E Ratio
- QSI N/A
- NMRA N/A
- Revenue Growth
- QSI 100.47
- NMRA N/A
- 52 Week Low
- QSI $0.61
- NMRA $0.61
- 52 Week High
- QSI $5.77
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- QSI 61.95
- NMRA 60.03
- Support Level
- QSI $1.44
- NMRA $1.70
- Resistance Level
- QSI $1.92
- NMRA $1.93
- Average True Range (ATR)
- QSI 0.16
- NMRA 0.13
- MACD
- QSI 0.03
- NMRA 0.02
- Stochastic Oscillator
- QSI 64.91
- NMRA 74.96
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.